Diabetes Dyslipidemia

Jonathan D. Schofield, Yifen Liu, Prasanna Rao-Balakrishna, Rayaz Malik, Handrean Soran

Research output: Contribution to journalReview article

49 Citations (Scopus)

Abstract

Diabetes mellitus is associated with a considerably increased risk of premature atherosclerotic cardiovascular disease. Intensive glycemic control has essentially failed to significantly improve cardiovascular outcomes in clinical trials. Dyslipidemia is common in diabetes and there is strong evidence that cholesterol lowering improves cardiovascular outcomes, even in patients with apparently unremarkable lipid profiles. Here, the authors review the pathophysiology and implications of the alterations in lipoproteins observed in both type 1 and type 2 diabetes, the effect of medications commonly used in the management of diabetes on the lipid profile, the evidence for lifestyle and pharmaceutical interventions, and national and international recommendations for the management of dyslipidemia in patients with diabetes.

Original languageEnglish
Pages (from-to)203-219
Number of pages17
JournalDiabetes Therapy
Volume7
Issue number2
DOIs
Publication statusPublished - 1 Jun 2016

Fingerprint

Dyslipidemias
Lipids
Lipoproteins
Life Style
Diabetes Mellitus
Cardiovascular Diseases
Cholesterol
Clinical Trials
Pharmaceutical Preparations

Keywords

  • Cardiovascular risk
  • Diabetes
  • Dyslipidemia
  • Lipoproteins
  • Low density lipoprotein cholesterol

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Schofield, J. D., Liu, Y., Rao-Balakrishna, P., Malik, R., & Soran, H. (2016). Diabetes Dyslipidemia. Diabetes Therapy, 7(2), 203-219. https://doi.org/10.1007/s13300-016-0167-x

Diabetes Dyslipidemia. / Schofield, Jonathan D.; Liu, Yifen; Rao-Balakrishna, Prasanna; Malik, Rayaz; Soran, Handrean.

In: Diabetes Therapy, Vol. 7, No. 2, 01.06.2016, p. 203-219.

Research output: Contribution to journalReview article

Schofield, JD, Liu, Y, Rao-Balakrishna, P, Malik, R & Soran, H 2016, 'Diabetes Dyslipidemia', Diabetes Therapy, vol. 7, no. 2, pp. 203-219. https://doi.org/10.1007/s13300-016-0167-x
Schofield JD, Liu Y, Rao-Balakrishna P, Malik R, Soran H. Diabetes Dyslipidemia. Diabetes Therapy. 2016 Jun 1;7(2):203-219. https://doi.org/10.1007/s13300-016-0167-x
Schofield, Jonathan D. ; Liu, Yifen ; Rao-Balakrishna, Prasanna ; Malik, Rayaz ; Soran, Handrean. / Diabetes Dyslipidemia. In: Diabetes Therapy. 2016 ; Vol. 7, No. 2. pp. 203-219.
@article{8bd2e29234b94d1698780b6c24c3cb47,
title = "Diabetes Dyslipidemia",
abstract = "Diabetes mellitus is associated with a considerably increased risk of premature atherosclerotic cardiovascular disease. Intensive glycemic control has essentially failed to significantly improve cardiovascular outcomes in clinical trials. Dyslipidemia is common in diabetes and there is strong evidence that cholesterol lowering improves cardiovascular outcomes, even in patients with apparently unremarkable lipid profiles. Here, the authors review the pathophysiology and implications of the alterations in lipoproteins observed in both type 1 and type 2 diabetes, the effect of medications commonly used in the management of diabetes on the lipid profile, the evidence for lifestyle and pharmaceutical interventions, and national and international recommendations for the management of dyslipidemia in patients with diabetes.",
keywords = "Cardiovascular risk, Diabetes, Dyslipidemia, Lipoproteins, Low density lipoprotein cholesterol",
author = "Schofield, {Jonathan D.} and Yifen Liu and Prasanna Rao-Balakrishna and Rayaz Malik and Handrean Soran",
year = "2016",
month = "6",
day = "1",
doi = "10.1007/s13300-016-0167-x",
language = "English",
volume = "7",
pages = "203--219",
journal = "Diabetes Therapy",
issn = "1869-6953",
publisher = "Springer Publishing Company",
number = "2",

}

TY - JOUR

T1 - Diabetes Dyslipidemia

AU - Schofield, Jonathan D.

AU - Liu, Yifen

AU - Rao-Balakrishna, Prasanna

AU - Malik, Rayaz

AU - Soran, Handrean

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Diabetes mellitus is associated with a considerably increased risk of premature atherosclerotic cardiovascular disease. Intensive glycemic control has essentially failed to significantly improve cardiovascular outcomes in clinical trials. Dyslipidemia is common in diabetes and there is strong evidence that cholesterol lowering improves cardiovascular outcomes, even in patients with apparently unremarkable lipid profiles. Here, the authors review the pathophysiology and implications of the alterations in lipoproteins observed in both type 1 and type 2 diabetes, the effect of medications commonly used in the management of diabetes on the lipid profile, the evidence for lifestyle and pharmaceutical interventions, and national and international recommendations for the management of dyslipidemia in patients with diabetes.

AB - Diabetes mellitus is associated with a considerably increased risk of premature atherosclerotic cardiovascular disease. Intensive glycemic control has essentially failed to significantly improve cardiovascular outcomes in clinical trials. Dyslipidemia is common in diabetes and there is strong evidence that cholesterol lowering improves cardiovascular outcomes, even in patients with apparently unremarkable lipid profiles. Here, the authors review the pathophysiology and implications of the alterations in lipoproteins observed in both type 1 and type 2 diabetes, the effect of medications commonly used in the management of diabetes on the lipid profile, the evidence for lifestyle and pharmaceutical interventions, and national and international recommendations for the management of dyslipidemia in patients with diabetes.

KW - Cardiovascular risk

KW - Diabetes

KW - Dyslipidemia

KW - Lipoproteins

KW - Low density lipoprotein cholesterol

UR - http://www.scopus.com/inward/record.url?scp=84975865348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975865348&partnerID=8YFLogxK

U2 - 10.1007/s13300-016-0167-x

DO - 10.1007/s13300-016-0167-x

M3 - Review article

VL - 7

SP - 203

EP - 219

JO - Diabetes Therapy

JF - Diabetes Therapy

SN - 1869-6953

IS - 2

ER -